TABLE 4.
Description of the Experiments |
m = Number of Mutations per Culture |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exp | Mutant | Cultures | Jackpots | Zeros | Mean | Median | Method | 1 | 2 | 3 | 4 | 5 | 7 | 8 |
phenotype | LD | LC | Drake | Jones | LC, | MSS, | ||||||||
p0 | mean | median | median | median | ML | ML | ||||||||
1 | Lac+ | 60 | 2 | 49 | 24 | 0 | m | 0.20 | 4.38 | 0.29 | 1.00 | UD | UD | 0.20 |
−95%CL | 0.10 | NA | 0.11 | |||||||||||
+95%CL | 0.36 | NA | 0.31 | |||||||||||
2 | Lac+ | 52 | 0 | 11 | 1.9 | 1 | m | 1.55 | 0.57 | 0.89 | 1.77 | 0.84 | 0.87 | 1.11 |
−95%CL | 1.06 | 0.89 | 0.77 | |||||||||||
+95%CL | 2.20 | 1.32 | 1.49 | |||||||||||
3 | RifR | 20 | 2 | 1 | 12.6 | 5.5 | m | 3.00 | 3.06 | 2.54 | 4.00 | 2.32 | 2.9 | 2.9 |
−95%CL | 1.40 | 1.70 | 1.90 | |||||||||||
+95%CL | 6.67 | 4.94 | 4.10 | |||||||||||
4 | RifR | 16 | 1 | 0 | 100 | 37.5 | m | NA | 17.7 | 10.4 | 14.2 | 9.2 | 11.2 | 11.0 |
−95%CL | 7.6 | 8.1 | ||||||||||||
+95%CL | 17.0 | 14.2 | ||||||||||||
5 | Lac+ | 30 | 1 | 13 | 2 | 1 | m | 0.84 | 0.67 | 0.89 | 1.77 | 0.84 | 0.44 | 0.71 |
−95%CL | 0.47 | 0.29 | 0.39 | |||||||||||
+95%CL | 1.37 | 0.89 | 1.09 | |||||||||||
6 | Lac+ | 30 | 3 | 6 | 15.3 | 1.5 | m | 1.61 | 3.32 | 1.14 | 2.08 | 1.04 | 1.04 | 1.23 |
−95%CL | 0.96 | 0.89 | 0.76 | |||||||||||
+95%CL | 2.56 | 1.69 | 1.77 | |||||||||||
5&6 | Lac+ | 60 | 4 | 19 | 8.6 | 1 | m | 1.15 | 1.84 | 0.89 | 1.77 | 0.84 | 0.72 | 0.95 |
−95%CL | 0.80 | 0.89 | 0.67 | |||||||||||
+95%CL | 1.59 | 1.32 | 1.27 |
UD = undefined; NA = not applicable; CL = Confidence limits. Lac+ = the ability to utilize lactose; RilR = resistance to rifampicin.